New drug for metastatic prostate cancer now also approved in Europe
On December 13, 2022, the European Commission granted approval to a drug against metastatic prostate cancer whose active ingredient was developed under the leadership of the German Cancer Research Center (DKFZ) in collaboration with Heidelberg University Hospital and Heidelberg University. The drug can significantly improve the survival chances of patients.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/neues-medikament-gegen-metastasierten-prostatakrebs-nun-auch-europa-zugelassen